Intestinal fatty acid binding protein (I-FABP) and CXC3L1 evaluation as biomarkers for patients at high-risk for coeliac disease in Johannesburg, South Africa

Gandini, Anastasia; Maayer, Tim De; Munien, Cameron; Bertrand, Katherine; Cairns, Ross; Mayne, Anthony; Gededzha, Maemu P.; Mayne, Elizabeth

doi:10.1016/j.cyto.2022.155945

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have observed that plasma levels of I-FABPs are high in CD patients compared to healthy individuals at diagnosis, indicating mucosal damage [53][54][55][56][57][58][59][60]. In fact, it has been proposed that patients who meet the four criteria for CD diagnosis (clinical picture of CD, tTG-IgA levels above 10 U/mL and IgA-EMA positivity, HLA-DQ2 and/or -DQ8 genotype and intestinal atrophy observed in the biopsy), together with an elevated serum level of I-FABPs, appear to suffer from CD; therefore, a diagnostic biopsy could be omitted in their case [55].…”

Section: Intestinal Fatty Acid-binding Proteins (I-fabps)mentioning

confidence: 99%

Global Approach to Follow-Up of Celiac Disease

Perez-Junkera,

Ruiz de Azua,

Vázquez-Polo

et al. 2024

Foods

View full text Add to dashboard Cite

Celiac disease, an autoimmune disorder induced by the ingestion of gluten, affects approximately 1.4% of the population. Gluten damages the villi of the small intestine, producing symptoms such as abdominal pain, bloating and a subsequent loss of nutrient absorption, causing destabilization of the nutritional status. Moreover, gluten can trigger extra intestinal symptoms, such as asthma or dermatitis, but also mental disorders such as depression or anxiety. Moreover, people suffering from celiac disease sometimes feel misunderstood by society, mainly due to the lack of knowledge about the disease and the gluten-free diet. Thus, the treatment and follow-up of patients with celiac disease should be approached from different perspectives, such as the following: (1) a clinical perspective: symptomatology and dietary adherence monitorization; (2) nutritional assessment: dietary balance achievement; (3) psychological assistance: mental disorders avoidance; and (4) social inclusion: educating society about celiac disease in order to avoid isolation of those with celiac disease. The aim of this narrative review is to gain deep insight into the different strategies that currently exist in order to work on each of these perspectives and to clarify how the complete approach of celiac disease follow-up should be undertaken so that the optimum quality of life of this collective is reached.

show abstract

Section: Intestinal Fatty Acid-binding Proteins (I-fabps)mentioning

confidence: 99%

Global Approach to Follow-Up of Celiac Disease

Perez-Junkera,

Ruiz de Azua,

Vázquez-Polo

et al. 2024

Foods

View full text Add to dashboard Cite

show abstract

“…One of them is the intestinal type (intestinal FABP), which is expressed throughout the gut and especially at the tip of the villi [24]. The use of this biomarker in noninvasive diagnosis and follow-up of CD [25][26][27][28][29] is based upon findings that increased levels of intestinal FAPB occur in the blood of individuals with damaged enterocytes, for example in cases of intestinal ischemia [30] or neonates with necrotizing enterocolitis [31].…”

Section: Fatty Acid-binding Proteinsmentioning

confidence: 99%

Celiac Disease: Promising Biomarkers for Follow-Up

Hrunka,

Janda,

Šťastná

et al. 2023

JGLD

View full text Add to dashboard Cite

Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.

show abstract

Intestinal fatty acid binding protein (I-FABP) and CXC3L1 evaluation as biomarkers for patients at high-risk for coeliac disease in Johannesburg, South Africa

Cited by 2 publications

References 39 publications

Global Approach to Follow-Up of Celiac Disease

Global Approach to Follow-Up of Celiac Disease

Celiac Disease: Promising Biomarkers for Follow-Up

Contact Info

Product

Resources

About